Three-Year Follow-Up Data for SPRYCEL®▼ (dasatinib) 100 mg Once-Daily Demonstrates Faster and Deeper Responses Compared With Imatinib 400 mg in Patients With Newly Diagnosed Philadelphia+ Chronic Myeloid Leukaemia in Chronic Phase

Three-Year Follow-Up Data for SPRYCEL®▼ (dasatinib) 100 mg Once-Daily Demonstrates Faster and Deeper Responses Compared With Imatinib 400 mg in Patients With Newly Diagnosed Philadelphia+ Chronic Myeloid Leukaemia in Chronic Phase PR Newswire PARIS, June 18, 2012 PARIS, June 18, 2012 /PRNewswire/ -- thResults Presented at 17 Congress of the European Hematology Association Bristol-Myers Squibb Company (NYSE:BMY) and Otsuka Pharmaceutical Europe Ltd., today announced results from the 3-year follow-up of the DASISION trial, ®which show that first-line treatment with SPRYCEL 100 mg results infaster and ®deeper response rates compared with Glivec (imatinib) 400 mg [as defined by time to achieve Complete Cytogenic Response (CCYR) or Major Molecular Response (MMR)]. Additionally, an exploratory landmark analysis of the study suggests that patients with a deeper molecular response at three months (defined as having a ≤ 10% BCR-ABL) show a trend towards improved outcomes [such as Progression Free Survival (PFS), Overall Survival (OS) and a lower risk of disease transformation to Accelerated Phase or Blast Phase (AP/BP)] than the patients who did not achieve this level of response at three months. In this analysis, a deeper molecular response at three months was achieved in 84% of [1]dasatinib treated patients and 64% of imatinib treated patients.